Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis
NCT04617925Phase 2Completed
- Start
- Feb 2021
- Primary completion
- Jul 2025
- Countries
- 6
01
Overview
Phase 2, open-label, single-arm trial of belantamab mafodotin in amyloid light chain amyloidosis. Primary endpoint: Overall Response Rate at 6 months. Started Feb 2021; status: completed.
02
Drugs
belantamab mafodotin
03
Conditions
amyloid light chain amyloidosis
Beyond the preview
Go deeper on NCT04617925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04617925.